A5065690508- CAR-T cell therapy research
- Immune Cell Function and Interaction
- RNA Interference and Gene Delivery
- Virus-based gene therapy research
- T-cell and B-cell Immunology
- Lymphoma Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Vascular Tumors and Angiosarcomas
Goethe University Frankfurt
2020-2025
Frankfurt Cancer Institute
2020-2025
University Hospital Frankfurt
2020-2025
German Red Cross
2024-2025
Deutschen Konsortium für Translationale Krebsforschung
2020
Autologous chimeric antigen receptor-modified (CAR) T cells with specificity for CD19 showed potent antitumor efficacy in clinical trials against relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL). Contrary to cells, natural killer (NK) kill their targets a non-antigen-specific manner do not carry the risk of inducing graft vs. host disease (GvHD), allowing application donor-derived an allogenic setting. Hence, unlike autologous CAR-T therapeutic CD19-CAR-NK can be generated...
Natural Killer (NK) cells are known for their high intrinsic cytotoxic capacity, and the possibility to be applied as 'off-the-shelf' product makes them highly attractive cell-based immunotherapies. In patients with multiple myeloma (MM), an elevated number of NK has been correlated higher overall-survival rate. However, cell function can impaired by upregulation inhibitory receptors, such immune checkpoint NKG2A. Here, we developed a CRISPR-Cas9-based gene editing protocol that allowed us...
ABSTRACT Natural killer (NK) cells are characterised by their ability to attack cancer without prior antigen stimulation. Additionally, clinical trials revealed great potential of NK expressing chimeric receptors (CARs). Successful anti‐tumour efficacy remains limited migration and infiltration the tumour site cell preparations, which is linked scarcity in knowledge dynamics invasion potential. Here, we applied a recently reported innovative microfluidic microchannel technology gain insight...
Nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL), is characterized by constitutional symptoms, advanced-stage disease, and generalized lymphadenopathy. A genetic hallmark of this lymphoma the frequent occurrence RHOA mutation G17V in neoplastic cells, which observed around 60% patients. Because involved both T-cell receptor downstream signalling migration, we hypothesized that characteristic presentation AITL could be result enhanced tumor migration. Therefore, study...
Topic: 24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research Background: CD33-targeting chimeric antigen receptor (CAR; CAR33)-T cells already showed efficacy for the treatment of acute myeloid leukemia (AML). Yet clinical application CAR33-T remains challenging due to its restriction autologous cell preparations potential risk severe side effects. In contrast, natural killer (NK) can be safely administered HLA-mismatched recipients possess an intrinsic...
Expression of chimeric antigen receptors (CAR) constitutes a promising approach to enhance therapeutic efficacy NK cells. Here, we demonstrate that primary CAR cells can be generated using the non-viral Sleeping Beauty (SB) transposon/transposase.